Technology from computing powerhouse Nvidia is already hard at work inside companies at the convergence of technology and biology, including the supercomputer driving Recursion Pharmaceutical’s drug ...

Recursion Pharmaceuticals (NASDAQ: RXRX), a biotech focused on artificial intelligence (AI), became a publicly traded company in 2021 -- a time when AI did not grab nearly as much attention (if any at ...

Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) were skyrocketing around 20% higher as of 11 a.m. ET on Friday. The big gain for the biotech stock came after the U.S. Food and Drug Administration ...

Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and financial profiles.

Recursion Pharmaceuticals' work could change the way that drugs are developed. Its pipeline features some exciting candidates, and it's partnering with major drugmakers. However, Recursion still needs ...

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...

What exactly does Recursion Pharmaceuticals do? It describes itself as a TechBio company, meaning it seeks to use technology to improve healthcare. Specifically, Recursion uses an artificial ...

For example, Nvidia owns stakes in six smaller companies. I think Recursion Pharmaceuticals (RXRX 2.48%) is arguably the most intriguing of the group. Recursion looks like a big dud so far. The ...

At a job interview on Friday, I had to write code, and one of the things that came up when we were talking about implementation of a concept was recursion. The director of the group said to me "Don't ...

For a biotech executive hoping to make something vast, Chris Gibson seems proudest in obsessing over the tiniest details. Gibson is the CEO of Recursion Pharmaceuticals, a biotech upstart aiming to ...

Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...

I have seen recursion code implode on itself on the JVM before. In this case, we caught the annoying stack overflow problem before it went into production and I had to work a good number of hours in ...